165 related articles for article (PubMed ID: 455885)
1. Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.
Sotaniemi EA; Anttila M; Pelkonen RO; Järvensivu P; Sundquist H
Clin Pharmacol Ther; 1979 Aug; 26(2):153-61. PubMed ID: 455885
[TBL] [Abstract][Full Text] [Related]
2. Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.
Pirttiaho HI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Anttila M; Sundqvist H
Br J Clin Pharmacol; 1980 Apr; 9(4):399-405. PubMed ID: 7378257
[TBL] [Abstract][Full Text] [Related]
3. Liver drug metabolism and blood pressure response to a lipophilic and hydrophilic beta blocker.
Säkö S; Sotaniemi EA; Anttila M
Eur J Drug Metab Pharmacokinet; 1986; 11(2):81-6. PubMed ID: 3770017
[TBL] [Abstract][Full Text] [Related]
4. Propranolol and sotalol metabolism after a drinking party.
Sotaniemi EA; Anttila M; Rautio A; Stengård J; Saukko P; Järvensivu P
Clin Pharmacol Ther; 1981 Jun; 29(6):705-10. PubMed ID: 7226702
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
Aro A; Anttila M; Korhonen T; Sundquist H
Eur J Clin Pharmacol; 1982; 21(5):373-7. PubMed ID: 7075642
[TBL] [Abstract][Full Text] [Related]
6. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
7. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
Branch RA; Shand DG; Wilkinson GR; Nies AS
J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
[TBL] [Abstract][Full Text] [Related]
8. Impaired elimination of propranolol due to right heart failure: drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity.
Ng CY; Ghabrial H; Morgan DJ; Ching MS; Smallwood RA; Angus PW
Drug Metab Dispos; 2000 Oct; 28(10):1217-21. PubMed ID: 10997943
[TBL] [Abstract][Full Text] [Related]
9. Sotalol: another beta adrenergic blocking agent?
Ahlquist RP
J Clin Pharmacol; 1979; 19(8-9 Pt 2):495-6. PubMed ID: 489768
[No Abstract] [Full Text] [Related]
10. [Treatment of arterial hypertension with sotalol, a beta-blocker (author's transl)].
Klein G; Schnelle K; Schinz A; Oberländer V
Dtsch Med Wochenschr; 1977 Apr; 102(15):563-9. PubMed ID: 849711
[TBL] [Abstract][Full Text] [Related]
11. Variable dose comparative trial of propranolol and sotalol in angina pectoris.
Horn ME; Prichard BN
Br Heart J; 1973 May; 35(5):555. PubMed ID: 4577278
[No Abstract] [Full Text] [Related]
12. Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.
Lemmer B; Winkler H; Ohm T; Fink M
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):42-9. PubMed ID: 2864639
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
Leahey WJ; Neill JD; Varma MP; Shanks RG
Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
[TBL] [Abstract][Full Text] [Related]
14. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.
Salmela PI; Sotaniemi EA; Pelkonen RO
Diabetes; 1980 Oct; 29(10):788-94. PubMed ID: 7439538
[TBL] [Abstract][Full Text] [Related]
16. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.
Ochs HR; Greenblatt DJ; Arendt RM; Schäfer-Korting M; Mutschler E
Arzneimittelforschung; 1985; 35(10):1580-2. PubMed ID: 2866772
[TBL] [Abstract][Full Text] [Related]
17. Impairment of antipyrine clearance in humans by propranolol.
Greenblatt DJ; Franke K; Huffman DH
Circulation; 1978 Jun; 57(6):1161-64. PubMed ID: 639239
[TBL] [Abstract][Full Text] [Related]
18. Influence of alaproclate on antipyrine metabolite formation in man.
Teunissen MW; Wahlén A; Vinnars E; Breimer DD
Eur J Clin Pharmacol; 1984; 27(4):447-52. PubMed ID: 6519152
[TBL] [Abstract][Full Text] [Related]
19. Propranolol in the treatment of angina: a review.
Prichard BN
Postgrad Med J; 1976; 52 Suppl 4():35-41. PubMed ID: 787954
[TBL] [Abstract][Full Text] [Related]
20. Likely explanation for longer duration of pharmacological (antianginal) effects of propranolol in relation to its short half-life.
Ishizaki T
Res Commun Chem Pathol Pharmacol; 1980 Feb; 27(2):223-39. PubMed ID: 7367746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
